Apr 20, 2015 by Brian Orelli, PhD3 Things to Slice and Dice in Intuitive Surgical's EarningsWatch Xi sales, trade-ins, and share repurchases to understand the company's long-term future.
Apr 18, 2015 by Brian Orelli, PhD, Sean Williams, and George Budwell, PhD3 Drug Stocks Leading the Charge Against Infectious DiseasesOur experts weigh in.
Apr 16, 2015 by Brian Orelli, PhD, Dan Caplinger, and Todd Campbell3 Potential Blockbuster Drugs That Could Be Approved Before Year's EndOur experts weigh in on some drug candidates with huge potential.
Apr 15, 2015 by Brian Orelli, PhD, Sean Williams, and George Budwell, PhD3 Biotech Stocks That May Disappear Before 2020Our experts weigh in.
Apr 12, 2015 by Brian Orelli, PhDThe Best Stock to Invest in Obesity DrugsMaking money helping people shed the pounds.
Apr 12, 2015 by Brian Orelli, PhDThis Is the Reason for Biotech's Monster Run, and It Isn't Going Away Anytime SoonFDA becomes Mr. Softy.
Apr 5, 2015 by Brian Orelli, PhD, Todd Campbell, and George Budwell, PhD3 Events That Could Sink the Biotech Sector This YearOur experts weigh in.
Apr 4, 2015 by Brian Orelli, PhD, Sean Williams, and Dan CaplingerFollowing Gilead Sciences, Inc., Which Biotech Will Pay a Dividend Next?Our experts weigh in.
Mar 30, 2015 by Brian Orelli, PhD, Todd Campbell, and George Budwell, PhDHealthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout TargetsOur experts weigh in.
Mar 23, 2015 by Brian Orelli, PhD, Dan Caplinger, and Todd Campbell3 Biotech Stocks to Buy If the Sector CrashesOur experts recommend Alnylam Pharmaceuticals, Celgene, and Biogen Idec.
Mar 23, 2015 by Brian Orelli, PhD, Todd Campbell, and George Budwell, PhD3 Big Pharma Stocks Wall Street Is Wrong AboutThree contributors weigh in.
Mar 22, 2015 by Brian Orelli, PhDConfessions of a Value Investor Stuck in a High-Growth IndustryIt's OK to buy premium-priced biotechs.
Mar 22, 2015 by Brian Orelli, PhD, Keith Speights, and George Budwell, PhDBest One-Drug Wonder Stock for 2015You've got to start somewhere. Here's our top picks of biotechs with just one drug on the market.
Mar 18, 2015 by Brian Orelli, PhDOrexigen Therapeutics, Inc. -- Stuck Between an Obese Rock and a Hard PlaceThe obesity drugmaker had good data that the FDA didn't want disclosed.
Mar 11, 2015 by Brian Orelli, PhD, Dan Caplinger, and Todd Campbell3 Biotech Stocks to Buy in MarchOur experts weigh in on why they like Vertex Pharmaceuticals, Neuralstem, and Intercept Pharmaceuticals.
Mar 8, 2015 by Brian Orelli, PhD, Dan Caplinger, and Todd Campbell3 Easy Ways to Fail When Investing in Biotech StocksOur experts help you avoid these common mistakes.
Mar 6, 2015 by Brian Orelli, PhD, Dan Caplinger, and Todd Campbell3 Big Pharma Stocks to Buy in MarchOur experts weigh in.
Mar 5, 2015 by Brian Orelli, PhDEmergent Biosolutions Inc's Unexpected SurpriseWith preannounced revenue and earnings, Emergent Biosolutions' fourth-quarter earnings were supposed to be boring.
Mar 5, 2015 by Brian Orelli, PhD5 Things MannKind Corporation's Management Wants You to KnowWhile info on Afrezza's launch was limited, some info on its next drugs flowed.
Mar 2, 2015 by Brian Orelli, PhDArena Pharmaceuticals, Inc. Earnings: Explaining the Wonky TrendsA fourth-quarter slowdown and relatively flat sales over the year.
